Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

1. O'Malley, D.M.
2. Matulonis, U.A.
3. Birrer, M.J.
4. Castro, C.M.
5. Gilbert, L.
6. Vergote, I.
7. Martin, L.P.
8. Mantia-Smaldone, G.M.
9. Martin, A.G.
10. Bratos, R.
11. Penson, R.T.
12. Malek, K.
13. Moore, K.N.